Dose Finding Trial of Rosuvastatin and Atorvastatin Versus Hepatitis C

This study has been completed.
Sponsor:
Information provided by:
Bader, Ted, M.D.
ClinicalTrials.gov Identifier:
NCT00446940
First received: March 11, 2007
Last updated: September 8, 2008
Last verified: September 2008
  Purpose

Different Doses of rosuvastatin and atorvastatin will be used to see if HCV viral load changes and liver tests change.


Condition Intervention Phase
Hepatitis C
Drug: rosuvastatin
Drug: atorvastatin
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Dose Finding Trial of Rosuvastatin and Atorvastatin Versus Hepatitis C

Resource links provided by NLM:


Further study details as provided by Bader, Ted, M.D.:

Estimated Enrollment: 16
Study Start Date: December 2006
Study Completion Date: March 2007
  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Hepatitis C

Exclusion Criteria:

  • HIV positivity
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00446940

Locations
United States, Oklahoma
VA Hospital
OKlahoma City, Oklahoma, United States, 73104
Sponsors and Collaborators
Bader, Ted, M.D.
Investigators
Principal Investigator: Ted Bader, MD VA Medical Center, Oklahoma City, OK
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00446940     History of Changes
Other Study ID Numbers: 13133
Study First Received: March 11, 2007
Last Updated: September 8, 2008
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Hepatitis
Hepatitis A
Hepatitis C
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Flaviviridae Infections
Atorvastatin
Rosuvastatin
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Anticholesteremic Agents
Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Enzyme Inhibitors
Lipid Regulating Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on July 29, 2014